同和药业上半年实现营收4.27亿元 同比增长11.88%

Core Viewpoint - Tonghua Pharmaceutical reported a mixed performance in its semi-annual report, with revenue growth but a decline in net profit, while maintaining a strong focus on R&D investment [1] Financial Performance - The company achieved an operating revenue of 427 million yuan, representing a year-on-year increase of 11.88% [1] - The net profit attributable to shareholders was 58.49 million yuan, showing a year-on-year decrease of 15.91% [1] - R&D investment amounted to 26.65 million yuan, up 20.14% year-on-year, accounting for 6.23% of the operating revenue [1] Sales Performance - Foreign sales reached 348 million yuan, an increase of 21.75 million yuan compared to the same period last year, with a growth rate of 6.66% [1] - Domestic sales were 79.09 million yuan, reflecting an increase of 23.62 million yuan year-on-year, with a growth rate of 42.59% [1] R&D Focus - The company has maintained an average R&D investment ratio of 8.34% of sales over the past three years [1] - Tonghua Pharmaceutical is actively increasing R&D efforts in various therapeutic areas, including anticoagulants, anti-hyperglycemic, anti-hypertensive, anti-gout, analgesics, anti-epileptic, anti-depressants, and digestive system medications [1]